疏肝汤剂防治大鼠肝纤维化作用的实验研究

采用疏肝软坚汤剂对大鼠肝纤化的防治作用进行了研究 ,从血清学和形态学方面观察了疏肝软坚汤剂对肝纤维化大鼠的影响 ,旨在探讨其抗肝纤维化的作用机制。结果表明 ,疏肝软坚汤剂可有效地防治大鼠肝纤维化 ,显著降低模型大鼠血清PCⅢ、HA、NAG含量 ,与对照组比较差异显著 ,且大剂量组肝脏形态学改变轻微。提示疏肝软坚汤有防治大鼠肝纤维化作用。     

薄层色谱－分光光度法测定柴胡疏肝散中柴胡皂甙a（d）的含量

采用薄层色谱－分光光度法测定了柴胡疏肝散中柴胡皂甙ａ（ｄ）的含量。样品通过聚酰胺吸附、溶剂萃取等方法进行预处理,采用硅胶ＧＦ２５４高效薄层板,展开剂为氯仿－正戊醇－甲醇－正丁醇醋酸,水（６０：３６：２２：９：４：２）,测定波长５４５ｎｍ。本法回收率为１００.２４％。     

New Protocol of Intermittent Androgen Deprivation Therapy for Patients With Metastatic Prostate Cancer: A Retrospective Study

BackgroundThe optimal points for halting and resuming treatment in intermittent androgen deprivation therapy (IADT) for metastatic prostate cancer patients are controversial.Patients and MethodsIn the 65 metastatic prostate cancer patients in group 1, androgen deprivation therapy was stopped when prostate-specific antigen (PSA) levels reached a nadir and was resumed when PSA levels doubled and ≥ 1.0 ng/mL (new protocol). In the 62 patients in group 2, androgen deprivation therapy was stopped 3 months after PSA = 0.2 ng/mL and resumed at PSA ≥ 4.0 ng/mL (Chinese Urological Association guideline). The total IADT duration, overall on-treatment and off-treatment time, tumor clinical progression ratio, performance status improvement, and treatment-related adverse effects were retrospectively analyzed.ResultsIn groups 1 and 2, the median total IADT durations were 51 and 46.5 months (significant difference, P = .006), median overall on-treatment times were 28 and 27.5 months (no significant difference, P > .05), and median overall off-treatment times were 23 and 19 months (significant difference, P < .001), respectively. Multivariate Cox regression analysis indicated that patients in group 1 had significantly higher progression-free-survival (hazard ratio, 0.634; P = .014). Two cases of clinical progression occurred group 1 and 5 in group 2; there was no significant difference (P > .05). There were no significant differences between the groups in terms of performance status improvement and treatment-related adverse effects.ConclusionThe new protocol was found to be beneficial, showing less biochemical/clinical progression, satisfactory performance status, and acceptable treatment-related adverse effects.     

蔡小荪辨治妇科疾病的创新思维

蔡小荪教授为蔡氏妇科传人,禀承家学,勤于实践,勇于探索,创立了蔡氏周期疗法、试管婴儿三步法、痛经辨证四异说等;临证不囿古法、擅长灵活遣药,不断丰富和发展了蔡氏妇科学。